Drug intelligence / Profile preview

meclofenoxate

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Meclofenoxate, also known as centrophenoxine, is a cholinergic nootropic compound used both as a dietary supplement and as a drug in some countries. It is an ester formed from dimethylaminoethanol (DMAE) and 4-chlorophenoxyacetic acid. Meclofenoxate acts primarily by increasing the availability of choline in the brain, which enhances acetylcholine synthesis—a neurotransmitter critical for memory and cognitive function. It has been studied for its potential to improve cognitive symptoms associated with dementia and age-related cognitive decline, with some evidence suggesting benefits in memory enhancement and neuroprotection. Meclofenoxate may also increase cellular membrane phospholipids and reduce age-associated lipofuscin accumulation in neural tissue. While it is available over-the-counter or by prescription depending on the country, clinical evidence supporting its efficacy remains limited[1][3][5].

Brand names
LucidrilProserylCetrexin
Other names
centrophenoxineclofenoxinclophenoxate
02

Targets

AcetylcholinesteraseButyrylcholinesteraseSIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on meclofenoxate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on meclofenoxate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call